INTRODUCTION
One of the main goals in histocompatibility research ought to be the identification of non-HLA loci important in graft-versus-host disease (GvHD) and graft rejection. Even if this were achieved, it would only help the clinician identify those patients with HLA-identical siblings who have a minimal risk of GvHD or graft rejection. Although an important contribution, it would not solve the problem of what to do for those patients who do not have an HLA-identical sibling donor who is also identical at these non-HLA loci. In fact, with increasing selectivity based on better typing, the number of these problem patients increases. For such patients who have no related donor, help could come from two directions:
1. The use of unrelated donors compatible for HL Α and non-HLA loci. However, we need to know whether matching for HLA between unrelated donor-recipient pairs can reach the same degree of compatibility as that between siblings. 2. More effective immunosuppression.
WHAT PROGRESS HAS BEEN MADE IN RECOGNIZING NON-HLA ANTIGENS?
Successful platelet transfusion holds a key position in bone marrow transplantation, especially in sustaining the patient during and after bone marrow transplantation. In hyperimmunized patients, only about 60 percent of the platelet transfusions will be successful if HLA-matched platelets are used (3).
The Seattle bone marrow transplant group has shown that GvHD is more serious in patients who are resistant to platelet transfusions (26). The possibility of matching for platelet antigens and preventing immunization to them are thus important goals in bone marrow transplantation and will be discussed first. Following the lead of the Seattle group, several studies have shown that the prognosis of bone marrow transplantation, especially as determined by GvHD, is poorer when the donor is a female and the recipient a male (Table 20-1) (1,11,26). The question one is confronted with is whether this is due to an in vitro detectable immunity against the H-Y antigen, as has been described in rodents. This question is especially relevant because not all sex-mismatched grafts fail because of GvHD, and such an in vitro test would make it possible to identify which donor-recipient pairs were at risk for GvHD. 
Therapeutic Approaches to Aplastic Anemia

H-Y IMMUNITY
Goulmy et al. studied six hyperimmunized women for evidence of anti-H-Y immunity using the cellmediated lympholyses (CML) test (16). They found significant evidence for such immunity in two patients, both of whom were suffering from aplastic anemia and one of whom had received a bone marrow transplant. It is of interest that this immunity is only evident when both the female effector cells and the male target cells carry HLA-A2 (Table 20 -2). It remains to be determined whether this test really predicts H-Y dependent GvHD. Nevertheless, its relevance in allograft reactions is emphasized by the finding that male donor-female recipient kidney grafts that share HLA-A2 have a 2-year graft survival of 38 percent, whereas if they both lack HLA-A2, it is 58 percent (15). The HLA-A2 restricted H-Y immunity is the first example in man of the dual recognition phenomen that has for some time been recognized in the mouse (33) . In mouse Systems, the restriction phenomenon has been described not only fr but also for microbial and artificial antigens The precise mechanism of the dual recognitic nomenon is not known. The HLA-A2 restricted H-Y immunity demonstrated for more than a year after ir zation, but it eventually wanes. It can, ho be reactivated in vitro by Stimulation with un HLA-A, HLA-B, and HLA-C identical, bul D different lymphocytes.
The serum from one of these patients (M was also examined for serological activity H-Y. The Standard, two-step complement-d ent cytotoxicity (CdC) technique was negati van Leeuwen was able to show that a tw fluorescence technique, which enabled the nition of CdC directed to identifiable sub mononuclear cells showed antibodies that ι with HLA-A2 male donors (Table 20- 
CELL-MEDIATE LYMPHOLYSIS
Positive Neg a. fraction of the mononuclear cells that were not typical B-cells were killed. The Interpretation of these two sets of data is difflcult. In the case of the CML reactiön, one can conceive of two hypotheses. In the first, the killer cell carries two receptors, one for HLA-A2 and one for H-Y. In the second, the killer cell carries one receptor directed to a neoantigen generated in an interaction between HLA-A2 and H-Y.
The serological reactions must be considered separately. Here, there are three possibilities. First, we would be dealing with two antibodies produced by two clones of B-cells directed to HLA-A2 and H-Y; second, we could be dealing with an antibody directed to an neoantigen produced by HLA-A2 and H-Y; and third, it could be that all three antibodies, HLA-A2, H-Y, and the antibody raised by the neoantigen, reacting together are needed for killing to occur. It should be possible to determine which of these situations exists.
It can be said that progress is being made in two areas that are relevant to bone marrow transplant survival. These are platelet alloantigens and immunity to sex-linked transplantation antigens. There are, of course, many more non-HLA Systems. The compatibility of some of these Systems, such as the ABO blood group System and the tissue System group Five, have been shown not to be relevant to bone marrow transplantation (4,21). For others, such as the granulocyte Systems (NA, NB, 14) and the endothelial and monocyte System E, relevancy has not been tested for (18, 19, 24) . For none of these Systems, with the exception of the ABO System, has it been ascertained by crossmatching procedures whether circulating antibodies against these Systems in the recipient could cause the rejection of the bone marrow graft. It appears to us to be a point of some urgency to find out whether this is so. The Seattle group and Jeannet have provided further evidence in that 51 Cr release studies, antibody-dependent CdC, as a sensitive indicator of cellular and humoral immunity of the recipient against the donor, correlated with graft rejection (32; Jeannet, personal communication). It is not known for which non-HLA System incompatibility was detected. Several other Systems in animals have been shown to be of possible relevance for bone marrow transplantation: the Hh and Mli Systems in the mouse and the colonic secretion System W/Z in the dog (7,12,34). Whether analogous Systems exist in man has not been determined. In this context, it is of significance that, for the detection of all these determinants, techniques other than the CdC technique are necessary. Furthermore, the target cells in these techniques will also be different from the mononuclear cell suspension routinely used in the CdC technique. The
CAN HLA-IDENTICAL, UNRELATED DONORS BE USED IN BONE MARROW TRANSPLANTATION?
The question can be answered, in all probability, in the affirmative. But only a few of these transplants have been attempted. With the possible exception of one case, none was successful (10). But ericouragement is given by a small number of mixed leukocyte culture (MLC) negative haplo-identical transplants (parent-child, siblings) from non-inbred families, several of which have been reported to be successful (6). It must be assumed that if it is possible to match successfully for one "unrelated" haplotype, it should also be possible to match for two. The lesson here is that if no HLA-identical sibling is available, one should not despair but look for other MLC-negative family members. An added advantage is that parents have a good chance of being identical for non-HLA loci.
The question then can be asked whether one should match for the SD or HLA-A, -B, and -C antigens or the MLC-stimulating determinants or both. In man, sufficient data are of course not available. Furthermore, no data are available for outbred mice and only limited data for the dog (27,31). Most critical would be studies in monkeys, which will probably soon be forthcoming.
Because bone marrow transplant data in experimental animals are lacking, it seems reasonable to ask whether other transplants in man may indicate what to expect. Table 20-4 summarizes experimental skin transplants in man, and these are a much more severe test of compatibility than are bone marrow transplants. It is clear that a negative MLC is a more effective way to improve skin graft survival than SD matching, but the combination of the two is still better. The 17-day mean graft survival that can be obtained in this manner is not much shorter than that obtained in HLA-identical siblings in our laboratory (19 days). Similar data are avail- TZ υ, Α ΙΛ h" ΗΤΓ anrt PI Τ and was then studied by sera recogmzing The panel was first typed for HLA D by HTC and PL1 ana was determmants The fit of the Β cell typmg w,th PLT «^ctedHTC ty^ng s rem rtfaMy« HTC nants 1t is clear that the sum of the gene frequencies of the HLA^C^»» ™ h names of t £ e inV estigators much smaller than .f the HLA D determmants had been ^^J^wrotog^ I£η ^ŵ ho made these sera available are given in parentheses The rematnder ot tne sera we able for kidney grafts (5) The question is, How does one obtain unrelated donors who are identical for the HLA-A, -B, and -C antigens and MLC negative with the recipient Large numbers of donors have been HLA typed, with the intention of using them for platelet and granulocyte support therapy, and some of these donors are wilhng to donate bone marrow In Europe alone, the files already exceed 50,000 HLA-typed donors Thus, lt would be possible to select, in many instances, for a given patient a donor who is at least HLA-A and -B matched Those donors who are MLC negative with the recipient could be further selected by direct MLC testing This is, however, a labonous procedure and when the patient has only a few lymphocytes, lt will be difficult lf not lmpossible to reahze Recently, lt has become possible to type for the alleles of the strong MLC-stimulating HLA-D locus usmg serological techniques (22) (Table 20 5) There are only eight alleles for HLA D (30) lt is quite possible that some of the HLA-D specificities will be split in two ormore determmants, as was the case for the HLA-A and Β locus antigens Nevertheless, as Table 20 Lourse, too early to know whether these findings can be used in the selection of unrelated donors for bone marrow transplantation, but lt IS equally clear that we ought to find out For the time being, our attitude should be one of extreme caution If at all possible, we should wait until data from Rhesus monkeys are available Until that time, only SDldentical, MLC-negative donors should be used and the CML test should also be negative
THE INFLUENCE OF SENSITIZATION ON THE EFFECTIVENESS OF IMMUNOSUPPRESSION
Gluckman et al have shown that the responsiveness of the patient, ι e , his or her capacity to form immunity against major histocompatibility complex (MHC) determinants and other antigens, and the effect immunosuppression has on this immunity, correlates with bone marrow graft prognosis and especially rejection (13) The immunological capacity of both patient and donor are thus variables to j reckon with, and the question whether we can ιη-fluence lt by other means than chemotherapy alone is thus a relevant one Although we know that anti-HLA-A, and -B antibodies in the recipient will de--stroy most kidney grafts from incompatible donors, lt is equally certain that kidney grafts in recipients who had received no blood transfusions before transplantation have a graft prognosis that is extremely poor less than 20 to 30 percent of the grafts function at 1 year in the non-transfused group, versus 70 percent in the transfused group (17,20) Bainer and his colleagues have confirmed these findmgs in a randomized prospective study in Rhesus > monkeys (9) The unexpected observation was that e whereas immunosuppression alone (Standard doses 0 of Imuran and prednisone) after transplantation had ι no effect on graft survival, the combination of lme munosuppression after transplantation with blood e transfusions before transplantation had a very sigd mficant effect (Figure 20-1) t
The mechamsm for this very effective graft pro-, longation is completely unclear (competition, s suppression cell induction, enhancing antibodies 7 ) ι But even if the mechamsm is unknown, lt might d still be of interest to test whether it could be used r -to suppress the GvH reactivity of the donoi, especially against non-HLA determinants It might be 1/ a relaüvely small pnce for the donor to pay if this could prevent GvHD in the reupient lble, have a nearly 100 percent survival rate, even in hypenmmunized patients The use of lymphocyte-free platelets for transfusion, which can be easily obtained by three-step differential centnfugation, prevents lmmunization in over 70 percent of the recipients
The cell mediated lympholysis (CML) test and a complement-dependent cytotoxicity (CdC) test can be used to detect HLA-restncted, anti-H-Y immunity in some lmmunized women This might explain, in part, the poorer prognosis of the sex-mismatched bone marrow giafts
In the future, if HLA-identical sibhngs of patients are not available or suitable for bone marrow transplantation, unrelated HLA-identical donors might take their place Chnical ddta obtained with other organ transplants indicate that prognosis when the donor is unrelated might be comparable or better than that of HLA-identical sibhng donors Thus, HLA-D-identical donors can be found relatively easily because it is now possible to type for HLA-D serologically The HLA-A, -B, and -Dldentical, donor-recipient pairs are in mixed leukocyte culture (MLC) negative about 80 percent of the cases If blood transfusions are combined with chemo-
